Lyra therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Watertown, mass., april 26, 2024 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (the “company” or “lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (crs), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of lyra therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with lyra therapeutics. the employment inducement awards were approved by lyra's independent directors serving on its compensation committee and granted under lyra's 2022 employment inducement award plan, as amended, and related form of stock option agreement in accordance with nasdaq listing rule 5635(c)(4).
LYRA Ratings Summary
LYRA Quant Ranking